Bulletin from Extraordinary General Meeting of Diamyd Medical AB
STOCKHOLM -- October 30, 2012
The Extraordinary General Meeting of Diamyd Medical AB (publ)(STO:DIAMB)(Pink
Sheets:DMYDY) held today decided in accordance with the Board's resolution, to
approve the agreement to sell all shares in the subsidiary, Diamyd, Inc. to
Periphagen Holdings, Inc.
About Diamyd Medical
Diamyd Medical was founded in 1996 and is active in the field of
pharmaceutical development. Diamyd Medical is headquartered in Stockholm,
Sweden. The Company’s development project within the area of diabetes consists
of the protein GAD65 for the treatment and prevention of autoimmune diabetes.
A Swedish researcher-initiated Phase II study is ongoing to evaluate whether
GAD65 can prevent type 1 diabetes in children who are at high risk of
developing the disease. The Company’s development projects for the treatment
of chronic pain and neuropathy uses the patented NTDDS (Nerve Targeting Drug
Delivery System) platform to administer therapeutic agents directly to the
nervous system. The NTDDS platform is being divested.
Diamyd Medical also has holdings in the companies Protein Sciences Corporation
(USA) and Mercodia AB (Sweden).
Diamyd shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm
(ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the
Pink OTC Markets and the Bank of New York Mellon (PAL). Further information is
available on the Company’s website: www.diamyd.com.
This information is disclosed in accordance with the Swedish Securities
Markets Act, the Swedish Financial Instruments Trading Act, or the
requirements stated in the listing agreements.
Diamyd Medical AB (publ)
Karlavägen 108, SE-115 26 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46
8 661 63 68
E-mail: email@example.com. Reg. no: 556530-1420
This information was brought to you by Cision http://www.cisionwire.com
Diamyd Medical AB
Peter Zerhouni, President and CEO
Phone: +46 8 661 00 26.
Press spacebar to pause and continue. Press esc to stop.